Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Liabilities and Shareholders Equity (2019 - 2025)

Cyclerion Therapeutics has reported Liabilities and Shareholders Equity over the past 7 years, most recently at $10.4 million for Q3 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $10.4 million for Q3 2025, up 17.05% from a year ago — trailing twelve months through Sep 2025 was $39.2 million (down 10.28% YoY), and the annual figure for FY2024 was $9.6 million, down 28.41%.
  • Liabilities and Shareholders Equity for Q3 2025 was $10.4 million at Cyclerion Therapeutics, up from $9.4 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for CYCN hit a ceiling of $100.0 million in Q1 2021 and a floor of $8.9 million in Q3 2024.
  • Median Liabilities and Shareholders Equity over the past 5 years was $13.4 million (2023), compared with a mean of $28.8 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 75.38% in 2023 and later rose 17.05% in 2025.
  • Cyclerion Therapeutics' Liabilities and Shareholders Equity stood at $59.3 million in 2021, then plummeted by 69.53% to $18.1 million in 2022, then dropped by 26.02% to $13.4 million in 2023, then fell by 28.41% to $9.6 million in 2024, then rose by 8.77% to $10.4 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $10.4 million (Q3 2025), $9.4 million (Q2 2025), and $9.8 million (Q1 2025) per Business Quant data.